Búsqueda Imágenes Maps Play YouTube Noticias Gmail Drive Más »
Iniciar sesión
Usuarios de lectores de pantalla: deben hacer clic en este enlace para utilizar el modo de accesibilidad. Este modo tiene las mismas funciones esenciales pero funciona mejor con el lector.

Patentes

  1. Búsqueda avanzada de patentes
Número de publicaciónUS3870790 A
Tipo de publicaciónConcesión
Fecha de publicación11 Mar 1975
Fecha de presentación25 Oct 1972
Fecha de prioridad22 Ene 1970
Número de publicaciónUS 3870790 A, US 3870790A, US-A-3870790, US3870790 A, US3870790A
InventoresLowey Hans, Stafford Herbert Henry
Cesionario originalForest Laboratories
Exportar citaBiBTeX, EndNote, RefMan
Enlaces externos: USPTO, Cesión de USPTO, Espacenet
Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
US 3870790 A
Resumen
A solid pharmaceutical composition in which the carrier consists essentially of hydroxypropylmethylcellulose, or hydroxypropylmethylcellulose admixed with up to about 20% ethylcellulose, is prepared by compressing a mixture comprising one therapeutic agent and the hydroxypropylmethylcellulose powder which has been humidified to a moisture content of from about 5 to about 25% by weight at a low compression pressure. The solid pharmaceutical composition obtained will release the active ingredient contained therein evenly over a prolonged period, e.g. from about 1 to 8 hours.
Imágenes(8)
Previous page
Next page
Descripción  (El texto procesado por OCR puede contener errores)

United States Patent [191 Lowey et al.

[ Mar. 11, 1975 SOLID PHARMACEUTICAL FORMULATIONS CONTAINING HYDROXYPROPYL METHYL CELLULOSE [75] Inventors: Hans Lowey, Mamaroneck; Herbert Henry Stafford, Staten lsland, both of N.Y.

[73] Assignee: Forest Laboratories, Inc., New

York, NY.

[22] Filed: Oct. 25, 1972 [21] Appl. No.: 300,745

Related U.S. Application Data [63] Continuation-in-part of Ser. No. 5,140, Jan. 22, 1970, abandoned, which is a continuation-in-part of Ser. No. 626.968, March 30, 1967, abandoned.

[56] References Cited UNITED STATES PATENTS 2,887,440 5/1959 Grcminger et a1 424/362 X 2,949,401 8/1960 Wershaw 424/362 X 3,181,998 5/1965 Kanig Cyr ct a1. Nurnbcrg 424/238 X Primary Examiner-Albert T. Meyers Assistant E.raminer-Leonard Schenkman [57] ABSTRACT A solid pharmaceutical composition in which the carrier consists essentially of hydroxypropylmethylcellulose, or hydroxypropylmethylcellulose admixed with up to about 20% ethylcellulose, is prepared by compressing a mixture comprising one therapeutic agent and the hydroxypropylmethylcellulose powder which has been humidified to a moisture content of from about 5 to about 25% by weight at a low compression pressure. The solid pharmaceutical composition obtained will release the active ingredient contained therein evenly over a prolonged period, e.g. from about 1 to 8 hours.

3 Claims, No Drawings SOLID PHARMACEUTICAL FORMULATIONS CONTAINING HYDROXYPROPYL METHYL CELLULOSE CROSS-REFERENCE This is a continuation-in-part of U.S. application Ser. No. 5,140, filed Jan. 22, 1970 now abandoned, which, in turn, is a continuation-in-part of U.S. application Ser. No. 626,968, filed Mar. 30, 1967, now abandoned.

DETAILED DESCRIPTION Sustained release products of conventional character are well known to the art and have been found to have a number of advantages. Specifically, the release of the medication contained therein is uniform and continuous over a period of time, thereby avoiding the necessity of frequent administration of the medicament while at the same time achieving a desired blood level of active ingredient. The preparation of sustained release compositions often requires a rather substantial and complicated procedure and often the degree ofpredictability and the release pattern are less than optimum.

The use of cellulose derivatives such as hydroxypropylmethylcellulose as an ingredient in pharmacetical formulations is of course known. Thus U.S. Pat. No. 3,266,992 describes the incorporation of up to 30% of various cellulose derivatives such as methylcellulose, sodium carboxymethylcellulose and hydroxyethylcellulose, the particular derivative depending upon the nature of the therapeutic agent, into tablets to effect rapid disintegration thereof. U.S. Pat. No. 2,887,440 on the other hand discloses the use of hydroxypropylmethylcellulose in enteric coatings to prevent disintegration of the tablet core. It has also been recognized that methylcellulose might itself be a desirable material for certain pharmaceutical formulations but attempts at achieving such products have not met with success. Thus U.S. Pat. No. 2,949,401 recognizes the desirable properties of methylcellulose in a buccal tablet containing vitamin A but limits the amount to from 3 to 5%. Trotter and coworkers report several unsuccessful attempts at directly compressing methylcellulose into a troche and succeeded only by incorporating 25% superfine sugar with the methylcellulose. Amer. Jour. Pharm, February 1956, pp. 5056. The combination of cellulose derivatives with large amounts of lactose is also described in U.S. Pat. No. 3,344,030. U.S. Pat. No. 3,590,117 reports the unsatisfactory nature of hydroxypropylmethylcellulose for troches. U.S. Pat. No. 3,312,594 describes troches containing carboxymethylcellulose but only in combination with equal amounts of pectin and gelatin.

The present invention relates to a long-acting sustained dosage unit, and the carriers and active ingredients in the composition thereof, presented in a solid coherent form. The long-acting dosage unit contains at least one active ingredient compressed with a mixture containing a moisturized carrier consisting esentially of 100 to 80% by weight of hydroxypropylmethylcellulose and optionally 0 to 20% by weight of ethylcellulose. The carrier ingredient during use gradually releases the active ingredient by contact with fluids, such as saliva, gastric juices, and other natural secretions and does so over an extended period, e.g., about 1 to 8 hours. In one aspect the invention comprises a long-acting troche, lozenge or tablet. The solid pharmaceutical form according to the present invention can however be utilized in other routes of administration in addition to buccal. Thus the solid form may be administered orally as a tablet to be swallowed or rectally or vaginally as a suppository.

Specifically, the carrier is hydroxypropylmethylcellulose which has been humidified under controlled conditions to a moisture content of from about 5 to about 25% by weight. This material, optionally containing ethylcellulose, can then be compressed at a low pressure, e.g. only 5 to 8 pounds per square inch, which, because of the moisture content, is sufficient to shape the material into a solid coherent pharmaceutical form such as a troche to be sucked or used in the oral cavity so as to effect a gradual release of the active therapeutic ingredient which is absorbed through the oral mucosa through the blood stream. Higher degrees of compression, e.g., up to about pounds per square inch, yield a harder and more long lasting composition as might be desired for example in a suppository to be inserted in the rectum or vagina, or a tablet to be simply swallowed.

According to the present invention it has now been found that a reliable and effective long acting sustained action solid dosage unit can be very simply made by compressing an appropriate amount of practically any desired active ingredient or medicament with a premoisturized hydroxypropylmethylcellulose powder or with a mixture of a combination of moisturized hydroxypropylmethylcellulose and ethylcellulose powder. The release time, the dosage unit and pattern of release can be controlled by the relative amounts of hydroxypropylmethylcellulose and ethylcellulose employed, the size and weight of the tablet product, the degree of compression or a combination thereof, bearing in mind that a high degree of moisturization permits the use of low compression pressures, and visa versa, for the blend of active ingredient and cellulose powder and that increased compression increases the compositions span of action. It is thus an important feature of the present invention that a sustained release product can be readily and easily prepared containing, as the sole carrier, varying amounts of hydroxypropylmethylcellulose and ethylcellulose having a predetermined moisture content and that by controlled variation of the moisture content of the alkylated cellulose carrier pow der, the duration of the release period of the active medicament held in the compacted tablet may be controlled. The release of the active ingredient is, therefore, controlled by the size and the weight, moisture content and degree of compression pressure exercised on the lozenge, suppository or tablet at the time it is being formed from the pre-wetted powder and active medicament.

In general, the long acting carrier products of the present invention are produced by combining the appropriate amount of active ingredient into the shape of troches, lozenges, tablets or suppositories with a mixture of from about -80% by weight of hydroxypropylmethylcellulose and from about 020% by weight of ethylcellulose. The product can also contain adjuvants such as a synthetic sweetening agent as for example saccharin, a nontoxic food grade color such as FD&C Yellow No. 10, a flavoring agent such as cherry flavor and a preservative such as pmethylbenzoic acid. The only criterion for the addition of such materials is that they do not tend to dehydrate the product before or after it is tableted by compression techniques.

Specific techniques for the manufacture and use of the long acting carrier will be set forth in greater detail below but an illustration of the improved activity of the product may briefly be noted by the following illustration. For example, a grain lozenge when held in the mouth will release its active ingredient in a regular manner over a period of one and one-and-one-half hours by dissolution or disintegration of the lozenge by the saliva fluids. If the same lozenge is inserted in the upper cavity of the mouth, the release then can be extended to 3 hours. Moreover a shaped product or tablet of the present invention which has a weight of about grains is noted to take almost twice as long to release its active ingredient as a 5 grain product.

When used as a lozenge, release through the action of the saliva is continuous and the active ingredient then passes through the gastro-intestinal tract into the blood stream. However, when the composition is positioned in the buccal pouch, absorption of the active ingredient takes place through the mucosa membrane lining the pouch directly through the capillaries in the blood stream.

A similar pattern can be observed when the solid pharamaceutical form takes the form of a suppository. Here again the exclusive carrier has highly desirable properties in that it is non-irritating, substantially neutral and adherent.

While the solid pharmaceutical forms of the present invention intended for oral administration; i.e., tablets to be swallowed, will be subjected to the effects of both gastric and intestinal fluids and mechanical wear within the gastrointestinal tract, a prolonged rate of release is also seen here.

The invention has flexibility and versatility dependent upon the particular nature of the active ingredient which is to be dispensed, the treatment or condition for which the active ingredient is indicated, the route of administration and the desired length of release time of the active ingredient. It has been found that one may for example prepare a 50 lb. mixture for the production of long acting troches from a composition indicated in the following Table:

TABLE No. Make of Materials Lbs. Ozs. Grs.

l 0.10% Calcium cyclamate 350 2 [00% Cherry Flavor 8 3 0.10% Methyl Paraben 350 4 0.01% Propyl Paraben 35 5 0.50% Lake Dye.Red No. 2 4 6 Mixture of 85% Methocel HG 6O 49 2 140 (20% of H 0), premium viscosity 50 and l5% Ethylcellulose N50 tions are not only permissible but are intended as these variations affect the release time and pattern of the active ingredient.

In preparing troches from the above mixture, items 1, 2, 3 and 4 are weighed out and thoroughly mixed. Item 5, which is the food grade dye, is placed in a mortar and rubbed with some of the mixture of Items 1, 2, 3 and 4 following which the remainder of Items 1, 2, 3 and 4 is added and the rubbing is conducted until a homogenous blend is obtained. Item 6, which is the specifled cellulose powder mixture, is added to the previously produced mixtures of Items 1, 2, 3, 4 and 5 and the entire composition is blended until uniformity is achieved. The uniform dry mixture of ingredients is then spread out on trays and thoroughly sprayed with a 35% mixture of ethanol and distilled water. The thus treated mixture is allowed to dry overnight and is then ground on a Fitzpatrick mill to an average 2040 mesh particle size. The powder derived from the Fitzpatrick mill is next placed on trays which trays are put into a steam room and held there overnight under conditions of very high humidity for the express purpose of creating in the previously dry blend, certain moisture levels which are important in the ultimate performance of each tablet in simultaneously maintaining its integrity and sustained even release of active ingredient. As a means of maintaining the desired humidity at a fixed level in the powder, trays filled with water are placed in the steam room to maintain the even consistency of the humidity level to insure adequate wetting of the powder. The room temperature is about F and humidity is maintained between about 78 to 82% for 24 hours (overnight). The resulting material will have a moisture content from about 20 to about 25% by weight.

After a constant moisture level is thus achieved, the active ingredient is added and the entire batch of material is placed in the hopper of a conventional tableting machine which is set up with half-inch punches and dies and the machine is adjusted and regulated for 8 pounds of pressure per square inch and for product size. In this manner, 7 /2 grain or 10 grain tablets preferably, are produced and by following the same procedure, but suitably further adjusting the machine, 12 grain or other size tablets are produced.

Alternatively, the procedure is carried out by introducing the hydroxypropylmethylcellulose or a mixture of the hydroxypropylmethylcellulose with ethylcellulose into an oven chamber having an exhaust aperture whichis at that time in closed or shut position. The chamber is provided with a heating unit and a forced air blower, which is inoperative at this stage of the procedure, the heat and forced air being applied at a subsequent stage. The material to be processed is placed in thin layers (not more than inch thick) on trays of the oven chamber which are lined with heat-resistant parchment paper and the trays are placed on racks in the oven chamber using only alternate shelves, thereby providing a predetermined amount of spacing between the layers of material being treated. There is then placed within the oven chamber a humidifier equipped with a humidistat which is pre-set to maintain humidity in the oven chamber at 85 the humidifier being filled with sufficient distilled or deionized water to last for 24 to 36 hours. The humidifier is now activated and the oven chamber is closed and the process is allowed to proceed under the 85 90% humidity for a minimum of 24 hours. Humidification can be continued for up to 36 hours or even longer if desired, although there is no special advantage in exceeding 36 hours and unduly extended times are apt to be uneconomical, but the treatment should be continued at least about 24 hours. The humidifier is then removed from the oven chamber, the exhaust aperture opened by manipulation of the valve and the forced air blower is activated thereby applying heat at a controlled temperature in the range of 100 to 120F (43 to 49C). The moisture content will then decrease, depending upon the length of time the mate rial is treated with the hot air. At the end of 12 hours for example the moisture content of the treated material is at its lowest limit of the range, about 5%. This is not an exact limit since this added moisture content can be as low as 4 or 4 6%, as determined by a standard moisture determination apparatus. The 12-hour period just referred to is also approximate as the duration of the period may vary somewhat above or below 12 hours, but it has been found in practice that the period should not exceed approximately 12 hours.

When the required added moisture content is achieved, the treated material is removed from the oven and passed through a No. 2 stainless steel screen employing a Fitzpatrick mill and processed as described above.

Variations in the two extremes are of course readily apparent, the critical factor being that the hydroxypropylmethylcellulose is so treated that its moisture content is stabilized at a higher level than is normally encountered.

The hydroxypropylmethylcellulose preferably employed is identified as Methocel HG 60 which is a commercial methylcellulose product manufactured by the Dow Chemical Company, Midland, Michigan and has a methoxyl percentage of 28 to 30%, a hydroxypropoxyl percentage of 7 to 12%, is soluble in water and organic solvents, has a normal gel temperature of 60F and demonstrates an average viscosity of 50 centipoises (range 40 to 60, 2% aqueous solution).

As regards the ethylcellulose, this material corresponds to that defined in the National Formulary XIII with a standard ethoxy content ranging between 44.0 and 51.0%, preferably 4849..5%, by weight. The preferred material corresponds to ethylcellulose N50, the number N50 indicating the viscosity in centipoises of a 5% by weight solution of the product in a 80/20 toluene/ethanol solvent at a temperature of 25C. These viscosity numbers are indicative of the size of the ethylcellulose molecules, the larger the molecule, the greater the viscosity and can be further referred to in the standard charts on the products which are readily available.

The active ingredient may be of any suitable nature such as insulin, vitamins, hormones, analgesics, local anesthetics, epinephrine, antiinflammatory steroids, progestational agents, antibiotics, antiseptics, antimycotics, antacids and the like. The nature of the therapeutic agent is not critical and any drug, or stable combination of drugs, can be incorporated into these novel pharmaceutical forms. This is particularly important since some active medicaments such as insulin, antidiuretic hormones and epinephrine become inactivated when incorporated into conventional or previously known sustained release products where the products are swallowed and the release occurs in the gastric fluids or in the intestinal fluids or in a combination of both. Some active agents such as ACTH, epinephrine, vitamin B iron insulin, antidiuretic hormones, prednisolone and nitroglycerine as well as antiobesity agents and antacids can, in accordance with the present invention, be administered via the transmucosal absorption route. However those therapuetic agents which are active when swallowed, can also be administered in the new pharmaceutical carrier of the present invention, the composition being used exactly like a conventional tablet. Similarly, antimicrobial agents such as furazolidone and nifuroxime can be administered in a vaginal suppository. Products of the present invention are also useful as demulcents in the treatment of painful ulcerations, inflammations, and irritations. These effects have been shown by in vitro and in vivo clinical tests.

Moreover, it can be shown by X-ray studies a tablet prepared according to the present invention for very long release, while gradually dissolving remains coherent for most of its passage through the gastro-intestinal tract. Hence a tablet of the moisturized hydroxypropylmethylcellulose and barium sulfate (as an X-ray contrast agent) having a total weight of 600 mg, a diameter of 12.7 mm, a thickness of 3.15 mm and a hardness of 6.6 lbs/in can still be seen in X-rays for more than 5 hours after administration. A typical progression is as follows:

1 hr. small intestine 1 hr. 35 min. do.

2 hr. 20 min. do.

5 hr. 10 min. caecum Since the therapeutic agent is being continuously released, the observed period of activity will be even longer than this.

The invention is further illustrated by the following non-limitative examples:

EXAMPLES l-ll SUSTAINED RELEASE TROCHE FORMULATIONS 50 LB. MIXTURE FOR 50,000 TABLETS AT 7 GRAINS EXAMPLE 1 PREDNISOLONE, 4 MG.

No. Make of Materials Lbs. Ozs. Grs.

l. Prednisolone 7 60 2. 0.10% Calcium Cyclamate 350 3. 1.00% Cherry Flavor 8 4. 0.10% Methyl Paraben 350 5. 0.01% Propyl Paraben 35 6. 0.50% Lake Dye Red No. 2 4 7. Methocel HG 6O 48 l l hydroxypropylmethylcellulose,

premium, viscosity 50,

moisture 20% by weight EXAMPLE 2 EPINEPHRINE, 1 MG No. Make of Materials Lbs. Ozs. Grs.

l. Epinephrine l 330 2. 0.10% Calcium Cyclamate 350 3. 1.00% Cherry Flavor 8 4. 0.10% Methyl Paraben 350 5. 0.01% Propyl Paraben 35 6. 0.50% Lake Dye Red No. 2 4 7. Methocel HG 60 49 245 EXAMPLE 2-C0ntinued EXAMPLE 7 EPIN EPHRINE, 1 MG No. Make of Materials Lbs. Ozs. Grs.

hydroxypropylmethylcellulose, premium,viscosity O moisture 20% by weight EXAMPLE 3 DIBUCAINE, 3 MG No. Make of Materials 1 L Ozs. Grs.

1. Dibucaine 5 I50 2. 0.10% Calcium cyclamate 350 3. 100% Cherry Flavor 8 4. 0.10% Methyl Paraben 350 5. 0.01% Propyl Paraben 35 6. 0.50% Lake Dye Red No. 2 4 7. Methocel HG 60 48 12 440 hydroxypropylmethylcellulose premium,viscosity 5O moisture 20% by weight EXAMPLE 4 BENZOCAINE, 20 MG No. Make of Materials Lbs. Ozs. Grs.

1. Benzocaine 2 3 300 2. 0.10% Calcium Cyclamate 350 3. 1.00% Cherry Flavor 8 4. 0.10% Methyl Paraben 350 5. 0.01% Propyl Paraben 35 6. 0.50% Lake Dye Red No. 2 4 7. Methocel HG 60 46 14 290 hydroxypropylmethylcellulose premium, viscosity 50 moisture 20% by weight EXAMPLE 5 TRIAMCINOLONE ACETONIDE, 0.25 MG No. Make of Materials Lbs. Ozs. Grs

1. Triamcinolone Acetonide 188 2. 0.10% Calcium Cyclamate 350 3. 1.00% Cherry Flavor 8 4. 0.10% Methyl Paraben 350 5. 0.01% Propyl Paraben 35 6. 0.50% Lake Dye Red No. 2 4 7. Methocel HG 60 49 1 402 hydroxypropylmethylcellulose premium, viscosity 50 moisture 20% by weight EXAMPLE 6 HEPARIN, 50 MG No. Make of Materials Lbs. Ozs. Grs.

1. Heparin 5 8 165 2. 0.10% Calcium Cyclamate 350 3. 1.00% Cherry Flavor 8 4. 0.10% Methyl Paraben 350 5. 0.01% Propyl Paraben 35 6. 0.50% Lake Dye Red No. 2 4 7. Methocel HG 6O 35 5 210 hydroxypropylmethylcellulose premium, viscosity 50, moisture 20% by weight 8. Ethocel N50 ethylcellulose 9 2 70 VITAMIN B12, 1000 MCG No. Make of Materials Lbs. 07s. Grs.

1. Vitamin B 1 330 2. 0.10% Calcium Cyclamate 350 3. 1.00% Cherry Flavor 8 4. 0.10% Methyl Paraben 350 5. 0.01% Propyl Paraben 35 6. 0.50% Lake Dye Red No. 2 4 7. Methocel HG 60 41 10 hydroxypropylmethylcelluose premium, viscosity 50 moisture 20% by weight 8. Ethocel N50 ethylcellulose 8 3 345 EXAMPLE 8 INSULIN, 250 INT. UNITS No. Make of Materials Lbs. Ozs. Grs.

l. Insulin 1 330 2. 0.10% Calcium Cyclamate 350 3. 1.00% Cherry Flavor 8 4. 0.10% Methyl Paraben 350 5. 0.01% Propyl Paraben 3S 6. 0.50% Lake Dye Red No. 2 4 7. Methocel HG 60 hydroxypropylmethylcellulose, premium, viscosity 50 moisture 20% by weight EXAMPLE 9 SODIUM BICARBONATE, 0.3 GM GRAIN TABLETS No. Make of Materials Lbs. Ozs. Grs.

1. Sodium Bicarbonate 33 1 23 2. 0.10% Calcium Cyclamate 350 3. 1.00% Cherry Flavor 8 4. 0.10% Methyl Paraben 350 5. 0.01% Propyl Paraben 35 6. 0.50% Lake Dye Red No. 2 4 7. Methocel HG 60 53 hydroxypropylmethylcellulose premium, viscosity 5O moisture 20% by weight 8. Ethocel N50 ethylcellulose 13 14 412 EXAMPLE l0 d-DESOXYEPHEDRINE HYDROCHLORIDE, 5 MG No. Make of Materials Lbs. Ozs. Grs.

1. d-Desoxyephedrine Hydrochloride 8 390 2. 0.10% Calcium Cyclamate 350 3. 1.00% Cherry Flavor 8 4. 0.10% Methyl Paraben 350 5. 0.01% Propyl Paraben 35 6. 0.50% Lake Dye Red No. 2 4 7. Methocel HG 60 49 7 45 hydroxypropylmethylcellulose, premium, viscosity 50 moisture 20% by weight In examples 1 10, the calcium cyclamate can be replaced by 0.1 the amount of sodium saccharin while the Lake Dye Red No. 2 can be replaced by another pharmaceutically acceptable coloring agent or omitted altogether from the formulation.

EXAMPLE ll REPRESENTATIVE RELEASE PATTERNS 260 individual tests have been made on 31 subjects with both lozenges and tablets inserted either in the buccal pouch on held sublingually, and show the following results:

LOZENGES Partial dissolution time Medium range per 1/10 gram carrier, 15.8 to 21.5 minutes. Medium range per 7 grain lozenge, 81 to 108 minutes. Medium range per 14 grain tablet, 158 to 215 minutes.

2. Total dissolution time.

3. Total dissolution time.

TABLETS INSERTED IN BUCCAL POUCH OR USED SUBLINGUALLY 1. Partial dissolution time. Medium range per 1/10 gram carrier, 29.4 to 42.1 minutes. Medium range per 7 grain tablet, 149 to 212 minutes. Medium range per 14 grain tablet, 294 to 421 minutes.

2. Total dissolution time.

3. Total dissolution time.

EXAMPLE 12 Analgesic Tablet Ingredients mg/tablet 1 Aspirin powder U.S.P. 525.0 2 Methocel HG 60 hydroxypropylmethylcellulose,

premium, viscosity 50, moisture 5% by weight 325.5 3. Glycine 45.0 4. Syloid 244 micron size silica 4.5

Ingredients 1, 2 and 3 are mixed in a bowl into which ingredient 4 is added after screening and the whole blended for 20 minutes and compressed in a tableting machine having a one-half inch die size and a one-half inch punch to make tablets with an average weight of 0.9 g and a thickness of 0.210 t 0.01 inch. The hardness of the tablet was 2228.6 lbs/square inch.

EXAMPLE l3 Antihistamine Tablet Ingredients mg/tablet l Chlorpheniramine maleate U.S.P. 12.60 2 Methocel HG 60 509.20

hydroxypropylmethylcellulose, premium. viscosity 50, moisture 4%% bylweight 3 Methyl paraben .S.P 0.52 4 Propyl faraben U.S.P. 0.06 5 Syloid 44 micron size silica 2.63

Ingredient 2 was placed in a container and ingredients l. 3, 4 and 5 were weighed out and added after screening and the whole blended for 20 minutes. The compression into tablets was conducted on a tableting machine using a die size of seven-sixteenths inch with a pound of seven-sixteenths inch to obtain a. tablet thickness of 0.250 t 0.01 inch with a tablet hardness of 2228.6 lbs/square inch. Each tablet weighed 0.525

3, 4 and 5 and the whole blended for 20 minutes and compressed as in Example 13. The tablet thickness was 0.250 $0.01 inch and the hardness was 22.2 lbs/square inch. Each tablet weighed 0.55 g.

EXAMPLE 15 Laxative Tablet Ingredients mg/tablet 1 Phenolphthalein U.S.P. 66.0 2 Methocel HG 60 480.64

hydroxypropylmethylcellulose,

premium, viscosity 50,

moisture 4% by weight 3 Methyl paraben U.S.P. 0.55 4 Propylgaraben U.S.P. 0.06 5 Syloid 44 2.75

The same procedure was followed as in Example 13 with the same results.

EXAMPLE 16 Vitamin Tablet Ingredients mg/tahlet Ascorbic acid, U.S.P., powder Methocel HG 60 hydroxypropylmethylcellulose, premium, viscosity 50, moisture 5% by weight 3 Syloid 244 g 4 Ingredients 1 and 2 were weighed out as in the preceding examples and placed into a stainless steel bowl into which ingredient 3 was added after screening and the whole blended for 20 minutes and compressed as previously described. The tablets had a thickness of 0.210 t 0.01 inch and a hardness of 22.2-28.6 lbs/square inch. Each tablet weighed 0.8 g.

EXAMPLE 17 Ingredients Amount/Suppository l Furazolidone 0.005 g 2 Nifuroxime 0.007 g 3 Methocel HG 60 1.988 g hydroxypropylmethylcellulose,

premium, viscosity 5 moisture 7.5% by weight The ingredients are thoroughly mixed and compressed in a similar fashion to that described above utilizing however a suppository mold to yield a vaginal suppository weighing 2 g.

The above ingredients are mixed and thoroughly blended for minutes and then compressed to for rectal suppositories of 1.14 g each.

What is claimed is:

l. A method of preparing a long-acting compressed buccal composition for the administration of transmucosally absorbed therapeutic agents consisting essentially of the therapeutic agent and a carrier which comprises subjecting an effective amount of a dry carrier consisting of from to of hydroxypropyl methyl cellulose having a methoxyl content of 28 to 30% and a hydroxypropyl content of 7 to 12% and from 20 to 0% of ethyl cellulose having an ethoxy content of 48 to 49.5% to controlled humidity for a time sufficient to establish a moisture content of from about 5 to about 25%, mixing the moisturized carrier with a therapeutically effective amount of the therapeutic agent and compressing the mixture into solid shaped units at a pressure of from about 5 to about 8 pounds per square inch.

2. The product prepared by the process of claim 1.

3. The product of claim 1 which additionally contains a synthetic sweetening agent, a coloring agent, a flavoring agent and a preservative.

UNITED STATES PATENT AND TRADEMARK OFFICE @ETTTTQATE PATENT NO. 3 870,,790 DATED Mamh 9 1975 iN\/ ENTOR(S) Hans Lowey 5: Herbert Henry Stafford It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

In Examples 6 7 and 9, the last line of each should read N50 Ethyleellulose by deleting "Ethocel".

' win. me we ismei a eom e. mm c. mesmu: ANN

Anminfi QT/RW v Commissioner oj'Parems and Trademarks

Citas de patentes
Patente citada Fecha de presentación Fecha de publicación Solicitante Título
US2887440 *12 Ago 195719 May 1959Dow Chemical CoEnteric coating
US2949401 *28 Jul 195816 Ago 1960Dome Chemicals IncBuccal tablet containing vitamin a
US3181998 *12 Ago 19604 May 1965Kanig Joseph LTablet disintegration
US3312594 *21 Jun 19634 Abr 1967Squibb & Sons IncLonglasting troche
US3424842 *4 May 196528 Ene 1969Merck Ag EManufacture of tablets directly from dry powders
Citada por
Patente citante Fecha de presentación Fecha de publicación Solicitante Título
US3976764 *11 Mar 197524 Ago 1976Eisai Co., Ltd.Solid therapeutic preparation remaining in stomach
US4163777 *29 Abr 19777 Ago 1979Lewis/Howe CompanyControlled antacid delivery form and method of treatment therewith
US4183898 *25 May 197815 Ene 1980Liff Lawrence JLiquid base makeup composition
US4188188 *27 Sep 197812 Feb 1980Bio-Rad Laboratories, Inc.Deparin, manganese or alkaline earth metal halide, polysaccharide, glucose polymer, vinylpyrrolidone polymer
US4226849 *14 Jun 19797 Oct 1980Forest Laboratories Inc.Sustained release therapeutic compositions
US4259314 *10 Dic 197931 Mar 1981Hans LoweyMethod and composition for the preparation of controlled long-acting pharmaceuticals
US4292300 *20 Jul 197729 Sep 1981Inveresk Research InternationalControlled release suppositories
US4349535 *11 Ene 198014 Sep 1982Liff Lawrence JWater, cellulose, chlorine dioxide; blood simulation
US4357469 *29 Jun 19812 Nov 1982Forest Laboratories, Inc.Carrier base material for prolonged release therapeutic compositions
US4369172 *18 Dic 198118 Ene 1983Forest Laboratories Inc.Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393 *26 Mar 198221 Jun 1983Forest Laboratories, Inc.Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4432975 *19 Oct 198121 Feb 1984Icn Pharmaceuticals, Inc.In mircolozenge to be dissolved in mouth
US4465660 *21 Dic 198214 Ago 1984Mead Johnson & CompanySustained release tablet containing at least 95 percent theophylline
US4529589 *29 Sep 198316 Jul 1985Davydov Anatoly BWith 5-((N-(3-methoxypyridazinyl)-6-sulphamido)-phenylazo)salicylic acid
US4540566 *2 Abr 198410 Sep 1985Forest Laboratories, Inc.Anionic surfactant
US4547358 *4 Jun 198415 Oct 1985Mead Johnson & CompanyTablet with thin cross section
US4647599 *9 Nov 19843 Mar 1987Egyt Gyogyszervegyeszeti CyarSustained release pharmaceutical tablets and process for the preparation thereof
US4668517 *4 Abr 198526 May 1987Norwich Eaton Pharmaceuticals, Inc.Furazolidone dosage form
US4680323 *1 Dic 198314 Jul 1987Hans LoweyMethod and composition for the preparation of controlled long-acting pharmaceuticals for oral administration
US4695591 *22 Nov 198522 Sep 1987Schering CorporationControlled release dosage forms comprising hydroxypropylmethylcellulose
US4713239 *19 Nov 198515 Dic 1987Vsesojuny Kardiologichesky Nauchny Tsentr Adkaemii Meditsinski Nauk SssrAbsorption through the mucous membranes of the mouth
US4764378 *10 Feb 198616 Ago 1988Zetachron, Inc.Matrices of high and low molecular weight polyoxyethylene glycols
US4775535 *4 Abr 19864 Oct 1988Hans LoweyMixing, compressing with cellulose ether carrier
US4786503 *6 Abr 198722 Nov 1988Alza CorporationDosage form comprising parallel lamine
US4803079 *20 Dic 19857 Feb 1989Syntex (U.S.A.) Inc.Controlled release naproxen and naproxen sodium tablets
US4842854 *13 May 198727 Jun 1989Vsesojuzny Kardiologichesky Nauchny Tsentr Akademii Meditsinskiki Nauk SsrSustained release delivery of drug directly to blood
US4851232 *8 Jun 198725 Jul 1989Alza CorporationDrug delivery system with means for obtaining desirable in vivo release rate pattern
US4855143 *12 Jul 19888 Ago 1989Hans LoweyMixing drug with cellulose ether, compression into tablet
US4880830 *9 Feb 198714 Nov 1989Ethical Pharmaceuticals LimitedSlow release formulation
US4921695 *9 Mar 19891 May 1990Babaian Eduard AAntianginal plate for treating ischemic heart disease
US4942040 *29 Sep 198817 Jul 1990Aktiebolaget HassleControlled and extended release agents for delivery of drugs of dihydropyridines or adrenoreceptor antagonist such as metoprolol
US4946685 *1 Sep 19887 Ago 1990Alza CorporationCellulosic dosage form
US4950484 *2 Mar 198821 Ago 1990Gist-Brocades N.V.Amphoteric beta-lactam antibiotic and cellulose disintegrants
US4983398 *15 Dic 19888 Ene 1991Forest Laboratories, Inc.Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates
US5028633 *21 Feb 19852 Jul 1991Freund Industrial Co., Ltd.Excipient for use in compression molding and process of preparation
US5126145 *11 Jun 199030 Jun 1992Upsher Smith Laboratories IncControlled release tablet containing water soluble medicament
US5204116 *1 May 199120 Abr 1993Alza CorporationDosage form providing immediate therapy followed by prolonged therapy
US5268181 *29 Jun 19927 Dic 1993Upsher-Smith Laboratories, Inc.Method of using niacin to control nocturnal cholesterol synthesis
US5292518 *16 Mar 19928 Mar 1994Hauser-KuhrtsProlonged-release drug tablet formulations
US5338550 *21 Dic 199216 Ago 1994Alza CorporationStereoisomer therapy
US5393765 *13 Dic 199328 Feb 1995Hoffmann-La Roche Inc.Pharmaceutical compositions with constant erosion volume for zero order controlled release
US5403593 *31 Mar 19924 Abr 1995Sandoz Ltd.Melt granulated compositions for preparing sustained release dosage forms
US5436009 *15 Dic 199225 Jul 1995Dagra Pharma B.V.Sustained release suppositories and a process for preparation
US5472712 *23 Jun 19935 Dic 1995Euroceltique, S.A.A drug substrate containing an active agent coated with ethyl cellulose being cured at a temperature greater than the glass transition temperature; storage stability, sustained release
US5478572 *6 Sep 199426 Dic 1995Bristol-Myers Squibb Co.Cellulosic polymer matrix and excipients; extended release; side effect reduction; antidepressants and anxiolytic agents
US5484607 *13 Oct 199316 Ene 1996Horacek; H. JosephExtended release clonidine formulation
US5672360 *22 Nov 199430 Sep 1997Purdue Pharma, L.P.24-hour sustained release dosage of morphine or morphine sulfate
US5681585 *20 Jun 199628 Oct 1997Euro-Celtique, S.A.Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5869100 *24 Jun 19979 Feb 1999Horacek; H. JosephTablet comprising clonidine, cellulose ether, adjunct selected from corn starch, lactulose, dextrose
US5879705 *18 Abr 19979 Mar 1999Euro-Celtique S.A.Analgesics for administering twice a day
US5948437 *28 May 19977 Sep 1999Zeneca LimitedPharmaceutical compositions using thiazepine
US5958459 *27 Nov 199528 Sep 1999Purdue Pharma L.P.Opioid formulations having extended controlled released
US5968551 *27 Jul 199519 Oct 1999Purdue Pharma L.P.Sustained release analgesics; bioavailibility
US6010718 *11 Abr 19974 Ene 2000Abbott LaboratoriesExtended release formulations of erythromycin derivatives
US6030642 *27 Jun 199729 Feb 2000Horacek; H. JosephExtended release clonidine formulation (capsule)
US6080428 *4 Ene 199527 Jun 2000Bova; David J.Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6103261 *6 Ene 199915 Ago 2000Purdue Pharma LpOpioid formulations having extended controlled release
US6129930 *6 Mar 199710 Oct 2000Bova; David J.Without causing treatment-limiting elevations in uric acid levels and/or glucose levels, by orally administering an antihyperlipidemic amount of niacin and an excipient to provide sustained release; fda orange book listed patent for niacin and simvastatin
US6129933 *24 Jul 199710 Oct 2000Purdue Pharma LpStabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US6143322 *8 Abr 19977 Nov 2000Purdue Pharma L.P.Method of treating humans with opioid formulations having extended controlled release
US6143328 *8 Mar 19997 Nov 2000Euro-Celtique, S.A.Sustained release compositions and a method of preparing pharmaceutical compositions
US621071028 Abr 19973 Abr 2001Hercules IncorporatedSustained release polymer blend for pharmaceutical applications
US624200313 Abr 20005 Jun 2001Novartis AgOrganic compounds
US62649747 Jul 199824 Jul 2001Salvagnini Italia SpaBuccal and sublingual administration of physostigmine
US62941957 Sep 199925 Sep 2001Purdue Pharma L.P.Orally administrable opioid formulations having extended duration of effect
US63064382 Jul 199823 Oct 2001Euro-Celtique, S.A.For therapy of pain; storgae stability
US637225228 Abr 200016 Abr 2002Adams Laboratories, Inc.Containing quantity of medicine in immediate release layer and second portion in release-delay matrix of hydrophilic polymer and water insoluble polymer
US643244717 May 200113 Ago 2002Novartis AgCore of fluvastatin, hydroxypropyl methyl cellulose and optionally other excipients, dosage form is color-stable during storage
US655161613 Oct 199922 Abr 2003Abbott LaboratoriesReducing gastrointestinal adverse side effects and improving taste
US657288526 Jun 20013 Jun 2003Euro-Celtique, S.A.Inert pharmaceutically acceptable substrates containing an annalgesic with diameter of .1 mm-3 mm, effective blood levels for at least 24 hours
US6592901 *15 Oct 200115 Jul 2003Hercules IncorporatedHighly compressible ethylcellulose for tableting
US664552719 Oct 200111 Nov 2003Euro-Celtique S.A.Stabilized sustained release tramadol formulations
US667696731 Oct 199713 Ene 2004Kos Pharmaceuticals, Inc.Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US673378330 Oct 200111 May 2004Euro-Celtique S.A.Controlled release hydrocodone formulations
US674669131 Oct 19978 Jun 2004Kos Pharmaceuticals, Inc.Intermediate release nicotinic acid formulation having a dissolution curve similarity fit factor of about 79, and in in vitro dissolution profile in deionized water at about 100rpm; time release agents; fda orange book listed patent for niacin and simvastatin
US680629423 Abr 200219 Oct 2004Euro-Celtique S.A.Formulated for sustained (rapid or delayed) release of tramadol (hydrochloride); uniformity
US681822931 Oct 199716 Nov 2004Kos Pharmaceuticals, Inc.Intermediate release nicotinic acid compositions for treating hyperlipidemia
US687240722 Nov 200229 Mar 2005Abbott LaboratoriesExtended release formulations of erythromycin derivatives
US690570912 Nov 200114 Jun 2005Purdue Pharma, LpStabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US695582115 Abr 200218 Oct 2005Adams Laboratories, Inc.Sustained release formulations of guaifenesin and additional drug ingredients
US712220421 Abr 200317 Oct 2006Advancis Pharmaceutical CorporationAntibiotic composition with inhibitor
US717948618 May 200120 Feb 2007Nostrum Pharmaceuticals, Inc.Preparing the granulated niacin by granulating and milling a powdered form of the niacin into granules; blending with a lubricant until the lubricant is substantially evenly dispersed in the mixture and compressing the mixture into a tablet
US727083120 Mar 200318 Sep 2007Purdue Pharma L.P.Orally administrable opioid formulations having extended duration of effect
US728222114 Nov 200516 Oct 2007Middlebrook Pharmaceuticals, Inc.Dosage forms of antiviral and a carrier; an immediate release dosage form and delayed release dosages, each initiates release at different times; product contains the total dosage of the antiviral for a twenty-four hour period
US731682118 Jun 20048 Ene 2008Purdue Pharma, L.P.A controlled release layered bead coated with an aqueuous ethyl cellulose dispersion; time-release agents; improved storage stability
US747640316 Jun 200413 Ene 2009Andrx Pharmaceuticals, LlcControlled release dosage form for a sparingly water soluble to insoluble drug, and a mixture of a low viscosity polymer and a higher viscosity polymer such as hydroxypropyl cellulose; clarithromycin for example; less food effect on bioavailability; side effect reduction
US751410011 Sep 20037 Abr 2009Purdue Pharma L.P.Controlled release hydrocodone formulations
US774088124 Jul 200022 Jun 2010Purdue Pharma LpMethod of treating humans with opioid formulations having extended controlled release
US78380324 Abr 200323 Nov 2010Reckitt Benckiser Inc.An expectorant drug delivery dosage forms comprises a sustained release portion and an immediate release portion; relieving from bronchial mucus accumulation
US788412210 Nov 20098 Feb 2011Shionogi Pharma, Inc.Extended release formulation and method of treating adrenergic dysregulation
US79431749 Jun 200417 May 2011Purdue Pharma L.P.Extended duration pain relief with rapid onset; twice daily dosage; tablets, capsules
US79854204 Abr 200326 Jul 2011Reckitt Benckiser Inc.Sustained release of guaifenesin combination drugs
US798542122 Jun 200526 Jul 2011Reckitt Benckiser Inc.Sustained release formulations of guaifenesin and additional drug ingredients
US799850623 May 200316 Ago 2011Kos Life Sciences, Inc.Dosing a hyperlipidemic with an effective anticholesterol amount of nicotinic acid once per day in the evening or at night; combined with a pharmaceutically acceptable carrier to form an oral solid dosage form; side effect reduction
US801250415 Abr 20036 Sep 2011Reckitt Benckiser Inc.Sustained release portion of unit dose containing guaifenesin, dextromethorphan and a release-delaying matrix contains a hydrophilic polymer and a water insoluble polymer, immediate release portion containing guaifenesin
US806267212 Ago 200422 Nov 2011Shionogi Inc.Antibiotic product, use and formulation thereof
US814281117 Feb 200927 Mar 2012Purdue Pharma L.P.Controlled release hydrocodone formulations
US823189828 Oct 201031 Jul 2012Purdue Pharma L.P.Controlled release hydrocodone formulations
US82363484 Feb 20047 Ago 2012Bennes, Inc.Throat lozenges and chewing gums containing an aqueous matrix of ethyl cellulose and an essential oil; cold remedies, sore throats, weight loss, smoking cessation
US824699620 Ago 200421 Ago 2012Shionogi Inc.comprising immediate release, sustained release and delayed release dosage forms, with each dosage forms having a different release profile, wherein each reaches a maximum concentration at different times
US82990527 May 200730 Oct 2012Shionogi Inc.Pharmaceutical compositions and methods for improved bacterial eradication
US830398713 Jul 20106 Nov 2012Novartis AgPharmaceutical compositions comprising fluvastatin
US830398816 Sep 20106 Nov 2012Shionogi Inc.Antifungal once-a-day product, use and formulation thereof
US831377520 Jul 200420 Nov 2012Shionogi Inc.Antibiotic product, use and formulation thereof
US831377620 Jul 200420 Nov 2012Shionogi Inc.Antibiotic product, use and formulation thereof
US83573948 Dic 200622 Ene 2013Shionogi Inc.Compositions and methods for improved efficacy of penicillin-type antibiotics
US836149928 Jun 201229 Ene 2013Purdue Pharma L.P.Controlled release hydrocodone formulations
US842593620 Jul 200423 Abr 2013Shionogi Inc.Antibiotic product, use and formulation thereof
US846071014 Sep 200411 Jun 2013Shionogi, Inc.Antibiotic product, use and formulation thereof
US855152020 Dic 20128 Oct 2013Purdue Pharma L.P.Controlled release hydrocodone
US86287973 Dic 200814 Ene 2014Andrx Pharmaceuticals, LlcOral extended-release composition
US864766724 May 201311 Feb 2014Purdue Pharma, L.P.Controlled release hydrocodone formulations
US871572123 May 20136 May 2014Purdue Pharma L.P.Controlled release hydrocodone
US87157271 Jul 20056 May 2014Shionogi Inc.Tablet for pulsed delivery
US875882011 Ago 200424 Jun 2014Shionogi Inc.Robust pellet
US87789244 Dic 200615 Jul 2014Shionogi Inc.Modified release amoxicillin products
US879116014 Sep 201229 Jul 2014Ferring B.V.Tranexamic acid formulations
US88093949 Jul 201219 Ago 2014Ferring B.V.Tranexamic acid formulations
DE3020724A1 *31 May 198029 Ene 1981Forest LaboratoriesTherapeutische praeparate mit retardwirkung
DE3246492A1 *16 Dic 198230 Jun 1983Forest LaboratoriesVerfahren zur herstellung therapeutischer praeparate auf der basis von hydroxypropylmethylzellulose mit verlaengertem freisetzungsverlauf
DE3309516A1 *17 Mar 19831 Dic 1983Forest LaboratoriesVerfahren zur herstellung therapeutischer praeparate mit anhaltender freisetzung auf der basis von hydroxypropylmethylzellulose mit hohem molekulargewicht
DE3834794A1 *12 Oct 198819 Abr 1990F SchieleinComposition for oral administration to treat psoriasis
WO1985004100A1 *22 Feb 198526 Sep 1985American Home ProdSustained release pharmaceutical capsules
WO2005060941A1 *21 Dic 20047 Jul 2005Matharu Amol SinghExtended release antibiotic composition
Clasificaciones
Clasificación de EE.UU.424/469, 424/436, 424/430, 514/777, 424/480
Clasificación internacionalA61K9/20
Clasificación cooperativaA61K9/2054
Clasificación europeaA61K9/20H6F2